Sign In
Buy RMD
$188.63
+2.34 (+1.26%)
At Close: Jun 18, 2026
ResMed beats estimates on strong sleep apnea device sales
06:07pm, Wednesday, 24'th Jan 2024
ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.
3 Stocks to Buy to Benefit From the Booming Sleep Industry
02:30pm, Tuesday, 23'rd Jan 2024
Google “How important is sleep?” and you get three billion results.
Why ResMed Is One Of My Top Picks In 2024
12:41am, Monday, 22'nd Jan 2024
I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
02:06pm, Friday, 19'th Jan 2024
Evaluate the expected performance of ResMed (RMD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics f
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
01:06pm, Wednesday, 17'th Jan 2024
Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.
Here's Why ResMed (RMD) is a Strong Growth Stock
11:16am, Wednesday, 17'th Jan 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
US FDA identifies recall of ResMed's respiratory devices as most serious
05:54pm, Thursday, 11'th Jan 2024
The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.
ResMed: A Buy For Investors Seeking Long-Term Rewards
09:40pm, Wednesday, 10'th Jan 2024
ResMed is a profitable company with steady growth and attractive margins, making it a solid investment opportunity. The company operates mainly in the sleep apnea market, which is expected to grow sig
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
04:05pm, Wednesday, 03'rd Jan 2024
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday,
ResMed: Down 60% With Tremendous Long-Term Potential
06:00am, Monday, 30'th Oct 2023
ResMed's shares have fallen 37% due to struggles with profitability and investor fears of weight loss drugs, but I believe in its long-term potential. The company reported a 16% increase in revenue an
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down
09:02am, Friday, 27'th Oct 2023
ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.
ResMed Inc. (RMD) Q1 2024 Earnings Call Transcript
09:52pm, Thursday, 26'th Oct 2023
ResMed Inc. (NYSE:RMD ) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executiv
ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:35pm, Thursday, 26'th Oct 2023
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Stree
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
06:48pm, Thursday, 26'th Oct 2023
ResMed (RMD) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.51 per share a year ago.
MedTech Earnings in the Age of Ozempic May Not Be That Bad
02:01pm, Tuesday, 17'th Oct 2023
September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.
